About Treace Medical Concepts, Inc.
https://www.treace.comTreace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.
CEO
John T. Treace
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 70
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:6.32M
Value:$17.05M
BLACKROCK INC.
Shares:4.07M
Value:$10.99M
BLACKROCK, INC.
Shares:3.68M
Value:$9.94M
Summary
Showing Top 3 of 130
About Treace Medical Concepts, Inc.
https://www.treace.comTreace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $50.21M ▲ | $55.38M ▲ | $-16.29M ▲ | -32.44% ▲ | $-0.26 ▲ | $-12.17M ▲ |
| Q2-2025 | $47.39M ▼ | $54.73M ▼ | $-17.4M ▼ | -36.71% ▼ | $-0.28 ▼ | $-13.5M ▼ |
| Q1-2025 | $52.57M ▼ | $57.48M ▲ | $-15.92M ▼ | -30.29% ▼ | $-0.25 ▼ | $-12.15M ▼ |
| Q4-2024 | $68.71M ▲ | $55.68M ▲ | $-501K ▲ | -0.73% ▲ | $-0.01 ▲ | $3.05M ▲ |
| Q3-2024 | $45.09M | $51.27M | $-15.36M | -34.07% | $-0.25 | $-11.89M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $57.42M ▼ | $196.59M ▼ | $107.4M ▼ | $89.19M ▼ |
| Q2-2025 | $69.29M ▼ | $206.44M ▲ | $108.83M ▲ | $97.61M ▼ |
| Q1-2025 | $76.09M ▲ | $205.85M ▼ | $100.5M ▼ | $105.34M ▼ |
| Q4-2024 | $75.68M ▼ | $217.09M ▲ | $104.2M ▼ | $112.89M ▲ |
| Q3-2024 | $82.8M | $212.92M | $108.02M | $104.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.29M ▲ | $-9.09M ▼ | $8.74M ▲ | $-10K ▼ | $-366K ▲ | $-11.9M ▼ |
| Q2-2025 | $-17.4M ▼ | $-3.05M ▼ | $-3.26M ▼ | $987K ▲ | $-5.32M ▼ | $-7.82M ▼ |
| Q1-2025 | $-15.92M ▼ | $4.2M ▲ | $-1.89M ▼ | $-282K ▼ | $2.02M ▲ | $655K ▲ |
| Q4-2024 | $-501K ▲ | $-4.21M ▲ | $3.42M ▼ | $26K ▲ | $-760K ▲ | $-7.28M ▲ |
| Q3-2024 | $-15.36M | $-11.84M | $5.76M | $8K | $-6.07M | $-14.71M |
CEO
John T. Treace
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 70
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:6.32M
Value:$17.05M
BLACKROCK INC.
Shares:4.07M
Value:$10.99M
BLACKROCK, INC.
Shares:3.68M
Value:$9.94M
Summary
Showing Top 3 of 130